Globon글로본

Globon remains loss-making on a trailing basis, with its shares down sharply over the past year and no recent news coverage in the data.

Globon runs a cosmetics business (including the RUE KWAVE skincare brand aimed at young women in China, Southeast Asia and the Middle East) and a fertilizer-related raw materials trading business. On trailing figures to H1 2026, revenue was about ₩15.3B with an operating loss of about ₩5.3B, and the company has a negative return on equity. The share price closed at ₩1,400 on 2026-10-16, well below its 52-week high of ₩3,345.

What stands out

• Trailing operating margin is -34.4% and net margin is -41.7%, so the company is still losing money at the operating level, and 2025 was also a loss year.
• Revenue fell 25.3% in 2025 to about ₩12.9B, after reaching ₩17.3B in 2024, and the 2024 profit was a one-off year with a 1.4% operating margin.
• Free cash flow on a trailing basis was about -₩4.2B, and cash was about ₩3.3B against liabilities of 131.2% of equity; borrowings are shown as not available in the data.
• The share price is down 45.6% over one year and 27% over three months; the price-to-book ratio is 2.1 and there is no dividend.
• Recent filings are mostly contract-related, including several major sales or supply contract filings from May to October 2026 and a few 5%+ holding reports, though the data does not explain their financial impact. No news headlines were available.

What to watch

• The next half-year and quarterly filings, to see whether operating losses narrow from the trailing -₩5.3B and whether free cash flow improves.
• Amendments and details of the recent major sales or supply contracts, including their size and whether they feed into revenue.
• Going-concern-type risks are not stated in the data, but the negative equity-related metrics, cash burn and the 131.2% liabilities-to-equity ratio are the main balance sheet points to monitor.